1
STATE OF OKLAHOMA
1
2
1st Session of the 60th Legislature (2025)
2
3
SENATE BILL 1030 By: Howard
3
4
4
5
5
6
AS INTRODUCED
6
7
An Act relating to prescription drug pricing;
7
creating the 340B Drug Pricing Nondiscrimination Act;
8
providing short title; defining terms; prohibiting
8
certain reimbursement rates; prohibiting certain
9
terms or conditions on a 340B entity; prohibiting
9
certain interference on certain patient choice;
10
prohibiting certain provisions in certain contracts;
10
requiring submission of certain cost data; providing
11
certain exceptions; prohibiting manufacturers or
11
distributors from limiting certain drug actions;
12
prohibiting certain contracts; providing for
12
promulgation of rules; establishing certain fines or
13
fees; providing certain exceptions; amending 36 O.S.
13
2021, Sections 6960 and 6962, as last amended by
14
Sections 1 and 2, Chapter 306, O.S.L. 2024 (36 O.S.
14
Supp. 2024, Sections 6960 and 6962), which relate to
15
definitions and compliance review; defining terms;
15
prohibiting certain provider requirements;
16
prohibiting certain billing modifier; prohibiting
16
certain modifications; prohibiting certain provider
17
exclusions; prohibiting participation in certain
17
networks; prohibiting basing certain decisions on
18
certain drug pricing; eliminating certain
18
contracting; amending Section 3, Chapter 38, O.S.L.
19
2022, as last amended by Section 4, Chapter 306,
19
O.S.L. 2024 (36 O.S. Supp. 2024, Section 6966.1),
20
which relates to violations; establishing certain
20
finality of certain claims; providing for
21
codification; and providing an effective date.
21
22
22
23
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
23
24
24
Req. No. 596 Page 1

1
SECTION 1. NEW LAW A new section of law to be codified
1
2
in the Oklahoma Statutes as Section 5400 of Title 36, unless there
2
3
is created a duplication in numbering, reads as follows:
3
4
This act shall be known and may be cited as the “340B Drug
4
5
Pricing Nondiscrimination Act”.
5
6
SECTION 2. NEW LAW A new section of law to be codified
6
7
in the Oklahoma Statutes as Section 5401 of Title 36, unless there
7
8
is created a duplication in numbering, reads as follows:
8
9
As used in this act:
9
10
1. “340B drug” means a drug that has been subject to any
10
11
reduced purchase price by a manufacturer pursuant to Section 256b of
11
12
Title 42 of the United States Code and is purchased by a covered
12
13
entity as defined in Section 256b(a)(4) of Title 42 of the United
13
14
States Code;
14
15
2. “340B entity” means an entity participating or authorized to
15
16
participate in the federal 340B drug pricing program, as described
16
17
in Section 256b of Title 42 of the United States Code, including its
17
18
pharmacy, or any pharmacy contracted with the participating entity
18
19
to dispense drugs purchased through the 340B drug pricing program;
19
20
3. “Distributor” means a person other than a manufacturer, a
20
21
manufacturer’s co-licensed partner, a third-party logistics
21
22
provider, or repackager engaged in wholesale distribution as defined
22
23
by Section 353(e)(4) of Title 21 of the United States Code as
23
24
amended by the Drug Supply Chain Security Act;
24
Req. No. 596 Page 2

1
4. “Manufacturer” means:
1
2
a. a person that holds an application approved under
2
3
Section 355 of Title 21 of the United States Code or a
3
4
license issued under Section 262 of Title 42 of the
4
5
United States Code for such product, or if such
5
6
product is not the subject of an approved application
6
7
or license, the person who manufactured the product,
7
8
b. a co-licensed partner of the person described in
8
9
subparagraph a of this paragraph that obtains the
9
10
product directly from a person described in this
10
11
subparagraph or subparagraph a of this paragraph,
11
12
c. an affiliate of a person described in subparagraph a
12
13
or b of this paragraph who receives the product
13
14
directly from a person described in this subparagraph
14
15
or in subparagraph a or b of this paragraph, or
15
16
d. a person who contracts with another to manufacture a
16
17
product;
17
18
5. “Pharmacy” means a pharmacy licensed by the State Board of
18
19
Pharmacy, provided patients who receive pharmacy care shall be
19
20
physically located in the state; and
20
21
6. “Pharmacy benefits manager” means a person that performs
21
22
pharmacy benefits management and any other person acting for such
22
23
person under a contractual or employment relationship in the
23
24
performance of pharmacy benefits management for a managed care
24
Req. No. 596 Page 3

1
company, nonprofit hospital, medical service organization, insurance
1
2
company, third-party payor, or a health program administered by a
2
3
department of this state.
3
4
SECTION 3. NEW LAW A new section of law to be codified
4
5
in the Oklahoma Statutes as Section 5402 of Title 36, unless there
5
6
is created a duplication in numbering, reads as follows:
6
7
A. With respect to reimbursement to a 340B entity for 340B
7
8
drugs, a health insurance issuer, pharmacy benefits manager, other
8
9
third-party payor, or its agent shall not:
9
10
1. Reimburse a 340B entity for 340B drugs at a rate lower than
10
11
that paid for the same drug to entities that are not 340B entities
11
12
or lower reimbursement for a claim on the basis that the claim is
12
13
for a 340B drug;
13
14
2. Impose any terms or conditions on any 340B entity with
14
15
respect to any of the following that differ from such terms or
15
16
conditions applied to non-340B entities on the basis that the entity
16
17
participates in the federal 340B drug pricing program set forth in
17
18
Section 256b of Title 42 of the United States Code or that a drug is
18
19
a 340B drug. Such terms and conditions shall include, but not be
19
20
limited to, any of the following:
20
21
a. fees, charges, clawbacks, or other adjustments or
21
22
assessments. For purposes of this subparagraph, the
22
23
term “other adjustments” includes placing any
23
24
additional requirements, restrictions, or unnecessary
24
Req. No. 596 Page 4

1
burdens upon the 340B entity that result in
1
2
administrative costs or fees to the 340B entity that
2
3
are not placed upon other entities that do not
3
4
participate in the 340B drug pricing program,
4
5
including affiliate pharmacies of the health insurance
5
6
issuer, pharmacy benefits manager, or other third-
6
7
party payor,
7
8
b. dispensing fees that are less than the dispensing fees
8
9
for non-340B entities,
9
10
c. restrictions or requirements regarding participation
10
11
in standard or preferred pharmacy networks,
11
12
d. requirements relating to the frequency or scope of
12
13
audits of inventory management systems,
13
14
e. requirements that a claim for a drug include any
14
15
identification, billing modifier, attestation, or
15
16
other indication that a drug is a 340B drug in order
16
17
to be processed or resubmitted unless it is required
17
18
by the Centers for Medicare and Medicaid Services or
18
19
the Oklahoma Health Care Authority for the
19
20
administration of the Oklahoma Medicaid program, or
20
21
f. any other restrictions, conditions, practices, or
21
22
policies that are not imposed on non-340B entities;
22
23
3. Require a 340B entity to reverse, resubmit, or clarify a
23
24
claim after the initial adjudication unless these actions are in the
24
Req. No. 596 Page 5

1
normal course of pharmacy business and not related to 340B drug
1
2
pricing;
2
3
4. Discriminate against a 340B entity in a manner that prevents
3
4
or interferes with any patient’s choice to receive such drugs from
4
5
the 340B entity, including the administration of such drugs. For
5
6
purposes of this subsection, it is considered a discriminatory
6
7
practice that prevents or interferes with a patient’s choice to
7
8
receive drugs at a 340B entity if a health insurance issuer,
8
9
pharmacy benefits manager, or other third-party payor places any
9
10
additional requirements, restrictions, or unnecessary burdens upon
10
11
the 340B entity including, but not limited to, requiring a claim for
11
12
a drug to include any identification, billing modifier, attestation,
12
13
or other indication that a drug is a 340B drug in order to be
13
14
processed or resubmitted unless it is required by the Centers for
14
15
Medicare and Medicaid Services or the Oklahoma Health Care Authority
15
16
in administration of the Oklahoma Medicaid program;
16
17
5. Include any other provision in a contract between a health
17
18
insurance issuer, pharmacy benefits manager, or other third-party
18
19
payor and a 340B entity that discriminates against the 340B entity
19
20
or prevents or interferes with an individual’s choice to receive a
20
21
prescription drug from 340B entity, including the administration of
21
22
the drug, in person or via direct delivery, mail, or other form of
22
23
shipment, or creation of a restriction or additional charge on a
23
24
patient who chooses to receive drugs from a 340B entity;
24
Req. No. 596 Page 6

1
6. Require or compel the submission of ingredient costs or
1
2
pricing data pertaining to 340B drugs to any health insurance
2
3
issuer, pharmacy benefits manager, or other third-party payor; or
3
4
7. Exclude any 340B entity from the health insurance issuer,
4
5
pharmacy benefits manager, or other third-party payor network on the
5
6
basis that the 340B entity dispenses drugs subject to an agreement
6
7
under Section 256b of Title 42 of the United State Code, or refuse
7
8
to contract with a 340B entity for reasons other than those that
8
9
apply equally to non-340B entities.
9
10
B. Nothing in this section applies to the Oklahoma Medicaid
10
11
program as payor when Medicaid provides reimbursement for covered
11
12
outpatient drugs as defined in Section 1396r-8(k) of Title 42 of the
12
13
United States Code.
13
14
SECTION 4. NEW LAW A new section of law to be codified
14
15
in the Oklahoma Statutes as Section 5403 of Title 36, unless there
15
16
is created a duplication in numbering, reads as follows:
16
17
A manufacturer or distributor shall not:
17
18
1. Deny, prohibit, condition, discriminate against, refuse, or
18
19
withhold 340B drug pricing for, or otherwise limit the dispensing,
19
20
purchase, ordering, delivery, or receipt of, a drug purchased to be
20
21
dispensed or administered under a contract pharmacy agreement; or
21
22
2. Prohibit a pharmacy from contracting or participating with a
22
23
340B entity by denying 340B pricing on, or the pharmacy’s access to,
23
24
24
Req. No. 596 Page 7

1
a drug that is manufactured by a manufacturer based on a pharmacy’s
1
2
relationship with a 340B entity.
2
3
SECTION 5. NEW LAW A new section of law to be codified
3
4
in the Oklahoma Statutes as Section 5404 of Title 36, unless there
4
5
is created a duplication in numbering, reads as follows:
5
6
The Attorney General may promulgate rules to effectuate the
6
7
provisions of this act and shall make recommendations to the
7
8
Insurance Commissioner for enforcement within the jurisdiction of
8
9
the Insurance Commissioner. In addition to or in lieu of any
9
10
applicable censure, suspension, or revocation of a license, a
10
11
manufacturer, distributor, health insurance issuer, pharmacy
11
12
benefits manager, other third-party payor, or its agent may be
12
13
subject to a civil fine not less than One Hundred Dollars ($100.00)
13
14
and not greater than Ten Thousand Dollars ($10,000.00) for each
14
15
violation of the provisions of this act. A violation occurs each
15
16
time a prohibited act is committed.
16
17
SECTION 6. NEW LAW A new section of law to be codified
17
18
in the Oklahoma Statutes as Section 5405 of Title 36, unless there
18
19
is created a duplication in numbering, reads as follows:
19
20
A. Nothing in this act shall be construed to be less
20
21
restrictive than federal law for a person or entity regulated by
21
22
this act.
22
23
B. Nothing in this act shall be construed to be in conflict
23
24
with applicable federal law and regulations or Oklahoma Statutes.
24
Req. No. 596 Page 8

1
C. Limited distribution of a drug required under Section 355-1
1
2
of Title 21 of the United States Code shall not be construed as a
2
3
violation of this act.
3
4
SECTION 7. AMENDATORY 36 O.S. 2021, Section 6960, as
4
5
last amended by Section 1, Chapter 306, O.S.L. 2024 (36 O.S. Supp.
5
6
2024, Section 6960), is amended to read as follows:
6
7
Section 6960. A. For purposes of the Patient’s Right to
7
8
Pharmacy Choice Act:
8
9
1. “Covered entity” means a nonprofit hospital or medical
9
10
service organization, for-profit hospital or medical service
10
11
organization, insurer, health benefit plan, health maintenance
11
12
organization, health program administered by the state in the
12
13
capacity of providing health coverage, or an employer, labor union,
13
14
or other group of persons that provides health coverage to persons
14
15
in this state. This term does not include a health plan that
15
16
provides coverage only for accidental injury, specified disease,
16
17
hospital indemnity, disability income, or other limited benefit
17
18
health insurance policies and contracts that do not include
18
19
prescription drug coverage;
19
20
2. “Health insurer” means any corporation, association, benefit
20
21
society, exchange, partnership or individual licensed by the
21
22
Oklahoma Insurance Code;
22
23
3. “Health insurer payor” means a health insurance company,
23
24
health maintenance organization, union, hospital and medical
24
Req. No. 596 Page 9

1
services organization or any entity providing or administering a
1
2
self-funded health benefit plan;
2
3
4. “Mail-order pharmacy” means a pharmacy licensed by this
3
4
state that primarily dispenses and delivers covered drugs via common
4
5
carrier;
5
6
5. “Pharmacy benefits manager” or “PBM” means a person,
6
7
business, or other entity that performs pharmacy benefits
7
8
management. The term shall include a person or entity acting on
8
9
behalf of a PBM in a contractual or employment relationship in the
9
10
performance of pharmacy benefits management for a managed care
10
11
company, nonprofit hospital, medical service organization, insurance
11
12
company, third-party payor or a health program administered by a
12
13
department of this state;
13
14
6. “Pharmacy benefits management” means a service provided to
14
15
covered entities to facilitate the provisions of prescription drug
15
16
benefits to covered individuals within the state, including, but not
16
17
limited to, negotiating pricing and other terms with drug
17
18
manufacturers and providers. Pharmacy benefits management may
18
19
include any or all of the following services:
19
20
a. claims processing, retail network management, and
20
21
payment of claims to pharmacies for prescription drugs
21
22
dispensed to covered individuals,
22
23
b. administration or management of pharmacy discount
23
24
cards or programs,
24
Req. No. 596 Page 10

1
c. clinical formulary development and management
1
2
services, or
2
3
d. rebate contracting and administration;
3
4
7. “Provider” means a pharmacy, as defined in Section 353.1 of
4
5
Title 59 of the Oklahoma Statutes or an agent or representative of a
5
6
pharmacy;
6
7
8. “Retail pharmacy network” means retail pharmacy providers
7
8
contracted with a PBM in which the pharmacy primarily fills and
8
9
sells prescriptions via a retail, storefront location;
9
10
9. “Rural service area” means a five-digit ZIP code in which
10
11
the population density is less than one thousand (1,000) individuals
11
12
per square mile;
12
13
10. “Spread pricing” means a prescription drug pricing model
13
14
utilized by a pharmacy benefits manager in which the PBM charges a
14
15
health benefit plan a contracted price for prescription drugs that
15
16
differs from the amount the PBM directly or indirectly pays the
16
17
pharmacy or pharmacist for providing pharmacy services;
17
18
11. “Suburban service area” means a five-digit ZIP code in
18
19
which the population density is between one thousand (1,000) and
19
20
three thousand (3,000) individuals per square mile; and
20
21
12. “Urban service area” means a five-digit ZIP code in which
21
22
the population density is greater than three thousand (3,000)
22
23
individuals per square mile;
23
24
24
Req. No. 596 Page 11

1
13. “340B drug” means a drug that has been subject to any
1
2
reduced purchase price by a manufacturer pursuant to Section 256b of
2
3
Title 42 of the United States Code and is purchased by a covered
3
4
entity as defined in Section 256b(a)(4) of Title 42 of the United
4
5
States Code; and
5
6
14. “340B entity” means an entity participating or authorized
6
7
to participate in the federal 340B drug pricing program, as
7
8
described in Section 256b of Title 42 of the United States Code,
8
9
including its pharmacy, or any pharmacy contracted with the
9
10
participating entity to dispense drugs purchased through the 340B
10
11
drug pricing program.
11
12
B. Nothing in the definitions of pharmacy benefits manager or
12
13
pharmacy benefits management as such terms are defined in the
13
14
Patient’s Right to Pharmacy Choice Act, the Pharmacy Audit Integrity
14
15
Act, or Sections 357 through 360 of Title 59 of the Oklahoma
15
16
Statutes shall be construed to deem the following entities to be a
16
17
pharmacy benefits manager:
17
18
1. An employer of its own self-funded health benefit plan,
18
19
except, to the extent permitted by applicable law, where the
19
20
employer without the utilization of a third party and unrelated to
20
21
the employer’s own pharmacy:
21
22
a. negotiates directly with drug manufacturers,
22
23
b. processes claims on behalf of its members, or
23
24
c. manages its own retail network of pharmacies; or
24
Req. No. 596 Page 12

1
2. A pharmacy that provides a patient with a discount card or
1
2
program that is for exclusive use at the pharmacy offering the
2
3
discount.
3
4
SECTION 8. AMENDATORY 36 O.S. 2021, Section 6962, as
4
5
last amended by Section 2, Chapter 306, O.S.L. 2024 (36 O.S. Supp.
5
6
2024, Section 6962), is amended to read as follows:
6
7
Section 6962. A. The Attorney General shall review and approve
7
8
retail pharmacy network access for all pharmacy benefits managers
8
9
(PBMs) to ensure compliance with Section 6961 of this title.
9
10
B. A PBM, or an agent of a PBM, shall not:
10
11
1. Cause or knowingly permit the use of advertisement,
11
12
promotion, solicitation, representation, proposal or offer that is
12
13
untrue, deceptive or misleading;
13
14
2. Charge a pharmacist or pharmacy a fee related to the
14
15
adjudication of a claim including without limitation a fee for:
15
16
a. the submission of a claim,
16
17
b. enrollment or participation in a retail pharmacy
17
18
network, or
18
19
c. the development or management of claims processing
19
20
services or claims payment services related to
20
21
participation in a retail pharmacy network;
21
22
3. Reimburse a pharmacy or pharmacist in the state an amount
22
23
less than the amount that the PBM reimburses a pharmacy owned by or
23
24
under common ownership with a PBM for providing the same covered
24
Req. No. 596 Page 13

1
services. The reimbursement amount paid to the pharmacy shall be
1
2
equal to the reimbursement amount calculated on a per-unit basis
2
3
using the same generic product identifier or generic code number
3
4
paid to the PBM-owned or PBM-affiliated pharmacy;
4
5
4. Deny a provider the opportunity to participate in any
5
6
pharmacy network at preferred participation status if the provider
6
7
is willing to accept the terms and conditions that the PBM has
7
8
established for other providers as a condition of preferred network
8
9
participation status;
9
10
5. Deny, limit or terminate a provider’s contract based on
10
11
employment status of any employee who has an active license to
11
12
dispense, despite probation status, with the State Board of
12
13
Pharmacy;
13
14
6. Retroactively deny or reduce reimbursement for a covered
14
15
service claim after returning a paid claim response as part of the
15
16
adjudication of the claim, unless:
16
17
a. the original claim was submitted fraudulently, or
17
18
b. to correct errors identified in an audit, so long as
18
19
the audit was conducted in compliance with Sections
19
20
356.2 and 356.3 of Title 59 of the Oklahoma Statutes;
20
21
7. Fail to make any payment due to a pharmacy or pharmacist for
21
22
covered services properly rendered in the event a PBM terminates a
22
23
provider from a pharmacy benefits manager network;
23
24
24
Req. No. 596 Page 14

1
8. Conduct or practice spread pricing, as defined in Section
1
2
6960 of this title, in this state; or
2
3
9. Charge a pharmacist or pharmacy a fee related to
3
4
participation in a retail pharmacy network including but not limited
4
5
to the following:
5
6
a. an application fee,
6
7
b. an enrollment or participation fee,
7
8
c. a credentialing or re-credentialing fee,
8
9
d. a change of ownership fee, or
9
10
e. a fee for the development or management of claims
10
11
processing services or claims payment services;
11
12
10. Discriminate, offer lower reimbursement, or impose any
12
13
separate terms upon a provider on the basis that a provider
13
14
participates in 340B drug pricing;
14
15
11. Require a provider to reverse, resubmit, or clarify a 340B
15
16
drug pricing claim after the initial adjudication unless these
16
17
actions are in normal course of pharmacy business and not related to
17
18
340B drug pricing;
18
19
12. Require a billing modifier to indicate that the drug or
19
20
claim is a 340B drug pricing claim, unless the drug or claim is
20
21
being billed to the Oklahoma Medicaid program;
21
22
13. Modify a patient copayment on the basis that the provider
22
23
of the patient participates in 340B drug pricing;
23
24
24
Req. No. 596 Page 15

1
14. Exclude a provider from a network on the basis that the
1
2
provider participates in 340B drug pricing;
2
3
15. Establish or set network adequacy requirements based on
3
4
340B drug pricing participation by a provider;
4
5
16. Prohibit a 340B entity or a pharmacy under contract with a
5
6
340B entity from participating in the network of the PBM on the
6
7
basis of participation in 340B drug pricing; or
7
8
17. Base the drug formulary or drug coverage decisions upon the
8
9
340B drug pricing status of a drug, including price or availability,
9
10
or whether a dispensing pharmacy participates in 340B drug pricing.
10
11
C. The prohibitions under this section shall apply to contracts
11
12
between pharmacy benefits managers and providers for participation
12
13
in retail pharmacy networks.
13
14
1. A PBM contract shall:
14
15
a. not restrict, directly or indirectly, any pharmacy
15
16
that dispenses a prescription drug from informing, or
16
17
penalize such pharmacy for informing, an individual of
17
18
any differential between the individual’s out-of-
18
19
pocket cost or coverage with respect to acquisition of
19
20
the drug and the amount an individual would pay to
20
21
purchase the drug directly, and
21
22
b. ensure that any entity that provides pharmacy benefits
22
23
management services under a contract with any such
23
24
health plan or health insurance coverage does not,
24
Req. No. 596 Page 16

1
with respect to such plan or coverage, restrict,
1
2
directly or indirectly, a pharmacy that dispenses a
2
3
prescription drug from informing, or penalize such
3
4
pharmacy for informing, a covered individual of any
4
5
differential between the individual’s out-of-pocket
5
6
cost under the plan or coverage with respect to
6
7
acquisition of the drug and the amount an individual
7
8
would pay for acquisition of the drug without using
8
9
any health plan or health insurance coverage., and
9
10
c. eliminate discriminatory contracting as it relates to:
10
11
(1) transferring the benefit of 340B drug pricing
11
12
savings from a 340B entity to another entity,
12
13
including without limitation pharmacy benefits
13
14
managers, private insurers, and managed care
14
15
organizations,
15
16
(2) offering a lower reimbursement rate for drugs
16
17
purchased under 340B drug pricing than for the
17
18
same drug not purchased under 340B drug pricing,
18
19
(3) refusal to cover drug purchases utilizing 340B
19
20
drug pricing,
20
21
(4) refusal to allow providers who utilize 340B drug
21
22
pricing to participate in networks, and
22
23
23
24
24
Req. No. 596 Page 17

1
(5) charging more than fair market value or seeking
1
2
profit sharing in exchange for services involving
2
3
340B drug pricing.
3
4
2. A pharmacy benefits manager’s contract with a provider shall
4
5
not prohibit, restrict, or limit disclosure of information or
5
6
documents to the Attorney General, law enforcement or state and
6
7
federal governmental officials investigating or examining a
7
8
complaint or conducting a review of a pharmacy benefits manager’s
8
9
compliance with the requirements under the Patient’s Right to
9
10
Pharmacy Choice Act, the Pharmacy Audit Integrity Act, and Sections
10
11
357 through 360 of Title 59 of the Oklahoma Statutes.
11
12
D. A pharmacy benefits manager shall:
12
13
1. Establish and maintain an electronic claim inquiry
13
14
processing system using the National Council for Prescription Drug
14
15
Programs’ current standards to communicate information to pharmacies
15
16
submitting claim inquiries;
16
17
2. Fully disclose to insurers, self-funded employers, unions or
17
18
other PBM clients the existence of the respective aggregate
18
19
prescription drug discounts, rebates received from drug
19
20
manufacturers and pharmacy audit recoupments;
20
21
3. Provide the Attorney General, insurers, self-funded employer
21
22
plans and unions unrestricted audit rights of and access to the
22
23
respective PBM pharmaceutical manufacturer and provider contracts,
23
24
24
Req. No. 596 Page 18

1
plan utilization data, plan pricing data, pharmacy utilization data
1
2
and pharmacy pricing data;
2
3
4. Maintain, for no less than three (3) years, documentation of
3
4
all network development activities including but not limited to
4
5
contract negotiations and any denials to providers to join networks.
5
6
This documentation shall be made available to the Attorney General
6
7
upon request; and
7
8
5. Report to the Attorney General, on a quarterly basis for
8
9
each health insurer payor, on the following information:
9
10
a. the aggregate amount of rebates received by the PBM,
10
11
b. the aggregate amount of rebates distributed to the
11
12
appropriate health insurer payor,
12
13
c. the aggregate amount of rebates passed on to the
13
14
enrollees of each health insurer payor at the point of
14
15
sale that reduced the applicable deductible,
15
16
copayment, coinsure or other cost sharing amount of
16
17
the enrollee,
17
18
d. the individual and aggregate amount paid by the health
18
19
insurer payor to the PBM for pharmacy services
19
20
itemized by pharmacy, drug product and service
20
21
provided, and
21
22
e. the individual and aggregate amount a PBM paid a
22
23
provider for pharmacy services itemized by pharmacy,
23
24
drug product and service provided; and
24
Req. No. 596 Page 19

1
6. Make drug formulary and coverage decisions based on the
1
2
normal course of business of the PBM, not based upon the 340B drug
2
3
pricing status of a drug, including price or availability, or
3
4
whether a dispensing pharmacy participates in 340B drug pricing.
4
5
E. Nothing in the Patient’s Right to Pharmacy Choice Act shall
5
6
prohibit the Attorney General from requesting and obtaining detailed
6
7
data, including raw data, in response to the information provided by
7
8
a PBM in the quarterly reports required by this section. The
8
9
Attorney General may alter the frequency of the reports required by
9
10
this section at his or her sole discretion.
10
11
F. The Attorney General may promulgate rules to implement the
11
12
provisions of the Patient’s Right to Pharmacy Choice Act, the
12
13
Pharmacy Audit Integrity Act, and Sections 357 through 360 of Title
13
14
59 of the Oklahoma Statutes.
14
15
SECTION 9. AMENDATORY Section 3, Chapter 38, O.S.L.
15
16
2022, as last amended by Section 4, Chapter 306, O.S.L. 2024 (36
16
17
O.S. Supp. 2024, Section 6966.1), is amended to read as follows:
17
18
Section 6966.1. A. The Insurance Commissioner may censure,
18
19
suspend, revoke, or refuse to issue or renew a license of or levy a
19
20
civil penalty against any person licensed under the insurance laws
20
21
of this state for any violation of the Patient’s Right to Pharmacy
21
22
Choice Act, Section 6958 et seq. of this title.
22
23
B. 1. If the Attorney General finds, after notice and
23
24
opportunity for hearing, that a pharmacy benefits manager (PBM)
24
Req. No. 596 Page 20

1
violated one or more provisions of the Patient’s Right to Pharmacy
1
2
Choice Act, the Pharmacy Audit Integrity Act or the provisions of
2
3
Sections 357 through 360 of Title 59 of the Oklahoma Statutes, the
3
4
Attorney General may instruct the Insurance Commissioner that the
4
5
PBM be censured or his or her license be suspended or revoked. If
5
6
the Attorney General makes such instruction, the Commissioner shall
6
7
enforce such action within thirty (30) days.
7
8
2. In addition to or in lieu of any censure or suspension or
8
9
revocation of a license by the Commissioner, the Attorney General
9
10
may levy a civil or administrative fine not less than One Hundred
10
11
Dollars ($100.00) and not greater than Ten Thousand Dollars
11
12
($10,000.00) for each violation of the provisions of the Patient’s
12
13
Right to Pharmacy Choice Act, the Pharmacy Audit Integrity Act or
13
14
the provisions of Sections 357 through 360 of Title 59 of the
14
15
Oklahoma Statutes.
15
16
3. The Attorney General may order restitution for economic loss
16
17
suffered by pharmacies or patients for violations of the Patient’s
17
18
Right to Pharmacy Choice Act, the Pharmacy Audit Integrity Act, or
18
19
the provisions of Sections 357 through 360 of Title 59 of the
19
20
Oklahoma Statutes.
20
21
C. Notwithstanding whether the license of a PBM has been
21
22
issued, suspended, revoked, surrendered or lapsed by operation of
22
23
law, the Attorney General is hereby authorized to enforce the
23
24
provisions of the Patient’s Right to Pharmacy Choice Act and impose
24
Req. No. 596 Page 21

1
any penalty or remedy authorized under the act against a PBM under
1
2
investigation for or charged with a violation of the Patient’s Right
2
3
to Pharmacy Choice Act, the Pharmacy Audit Integrity Act, the
3
4
provisions of Sections 357 through 360 of Title 59 of the Oklahoma
4
5
Statutes or any provision of the insurance laws of this state.
5
6
D. Each day that a PBM conducts business in this state without
6
7
a license from the Insurance Department shall be deemed a violation
7
8
of the Patient’s Right to Pharmacy Choice Act.
8
9
E. 1. All hearings conducted by the Office of the Attorney
9
10
General pursuant to this section shall be public and held in
10
11
accordance with the Administrative Procedures Act.
11
12
2. Hearings shall be held at the Office of the Attorney General
12
13
or any other place the Attorney General may deem convenient.
13
14
3. The Attorney General, upon written request from a PBM
14
15
affected by the hearing, shall cause a full stenographic record of
15
16
the proceedings to be made by a competent court reporter. This
16
17
record shall be at the expense of the PBM.
17
18
4. The ordinary fees and costs of the hearing examiner
18
19
appointed pursuant to Section 319 of this title may be assessed by
19
20
the hearing examiner against the respondent unless the respondent is
20
21
the prevailing party.
21
22
F. Any PBM whose license has been censured, suspended, revoked
22
23
or denied renewal or who has had a fine levied against him or her
23
24
shall have the right of appeal from the final order of the Attorney
24
Req. No. 596 Page 22

1
General, pursuant to Section 318 et seq. of Title 75 of the Oklahoma
1
2
Statutes.
2
3
G. If the Attorney General determines, based upon an
3
4
investigation of complaints, that a PBM has engaged in violations of
4
5
the provisions of the Patient’s Right to Pharmacy Choice Act, the
5
6
Pharmacy Audit Integrity Act, and Sections 357 through 360 of Title
6
7
59 of the Oklahoma Statutes with such frequency as to indicate a
7
8
general business practice, and that the PBM should be subjected to
8
9
closer supervision with respect to those practices, the Attorney
9
10
General may require the PBM to file a report at any periodic
10
11
interval the Attorney General deems necessary.
11
12
H. 1. The Attorney General shall have the authority to collect
12
13
all fines, penalties, restitution, and interest thereon pursuant to
13
14
the provisions of the Patient’s Right to Pharmacy Choice Act, the
14
15
Pharmacy Audit Integrity Act, and the provisions of Sections 357
15
16
through 360 of Title 59 of the Oklahoma Statutes, or any other
16
17
charge, cause of action, prelitigation settlement, or other
17
18
settlement that requires the recovery of money as a result of
18
19
violations of the Patient’s Right to Pharmacy Choice Act. Funds
19
20
collected by the Attorney General pursuant to the Patient’s Right to
20
21
Pharmacy Choice Act, the Pharmacy Audit Integrity Act, and Sections
21
22
357 through 360 of Title 59 of the Oklahoma Statutes shall be
22
23
deposited into the Attorney General’s Pharmacy Benefits Manager
23
24
Enforcement Revolving Fund created in Section 5 of this act.
24
Req. No. 596 Page 23

1
2. Costs of investigation, litigation, attorney fees, and other
1
2
expenses incurred shall be retained by the Office of the Attorney
2
3
General. Remaining funds shall be distributed to pharmacists,
3
4
patients, or other injured parties as determined by the Attorney
4
5
General.
5
6
3. The Attorney General shall promulgate rules for the
6
7
distribution of funds pursuant to this subsection.
7
8
I. All claims processed by a PBM on behalf of a provider that
8
9
participates in 340B drug pricing or on behalf of a 340B entity
9
10
shall be deemed final at the point of adjudication.
10
11
SECTION 10. This act shall become effective November 1, 2025.
11
12
12
13
60-1-596 CAD 1/16/2025 2:29:23 PM
13
14
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 596 Page 24

[DELETED:  P B H]
[DELETED:  P]
[DELETED:  P a a a a]
[DELETED:  P f]
[DELETED:  P d r r r a]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P c a]
[DELETED:  P c r]
[DELETED:  P n p m]
[DELETED:  P t e t]
[DELETED:  P t t]
[DELETED:  P a a a a a]
[DELETED:  P n e]
[DELETED:  P e t o r r]
[DELETED:  P c]
[DELETED:  P t t t t t]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P C 1]